Our previous study has shown that a panel of 12 genes including ERCC1, hMLH1, ATM, CDKN2B (p15INK4B), p14ARF, CDKN2A (p16INK4A), RASSF1A, RUNX3, GATA6, NDRG2, PTEN, and RARβ might be useful in evaluation of glioma aggressiveness. The gene discussed is CDKN2A; the disease is glioma.